Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:6120143.
doi: 10.1155/2016/6120143. Epub 2016 Apr 7.

Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Saleem Ahmed  1 , Nurun Nisa de Souza  2 , Wang Qiao  3 , Meidai Kasai  4 , Low Jee Keem  5 , Vishal G Shelat  5
Affiliations
Review

Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Saleem Ahmed et al. HPB Surg. 2016.

Abstract

Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers worldwide. Majority of patients with HCC are diagnosed in the advanced stages of disease and hence they are only suitable for palliative therapy. TACE (transarterial chemoembolization) is the most commonly used treatment for unresectable HCC. It is however unclear if TACE improves the quality of life (QoL) in patients with HCC. The aim of this review is to evaluate the impact of TACE on QoL of HCC patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection.
Figure 2
Figure 2
Factors influencing QoL in HCC patients treated with TACE.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bosch F. X., Ribes J., Cléries R., Díaz M. Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease. 2005;9(2):191–211. doi: 10.1016/j.cld.2004.12.009. - DOI - PubMed
    1. Salem R., Gilbertsen M., Butt Z., et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clinical Gastroenterology and Hepatology. 2013;11(10):1358.e1–1365.e1. doi: 10.1016/j.cgh.2013.04.028. - DOI - PubMed
    1. Heffernan N., Cella D., Webster K., et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. Journal of Clinical Oncology. 2002;20(9):2229–2239. doi: 10.1200/jco.2002.07.093. - DOI - PubMed
    1. Takayasu K., Arii S., Ikai I., et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131(2):461–469. doi: 10.1053/j.gastro.2006.05.021. - DOI - PubMed
    1. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology. 2012;56(4):908–943. doi: 10.1016/j.jhep.2011.12.001. - DOI - PubMed

LinkOut - more resources